Safer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly and Company
LLY
Current price
$701.23
As the manufacturer of Kisunla, Eli Lilly is the primary beneficiary of the FDA's approval for a safer dosing schedule, which is expected to increase ...
As the manufacturer of Kisunla, Eli Lilly is the primary beneficiary of the FDA's approval for a safer dosing schedule, which is expected to increase physician adoption and boost sales.
Biogen Inc.
BIIB
Current price
$138.60
A key competitor with its Alzheimer's drug Leqembi; Lilly's improved safety profile intensifies competition but also validates and expands the overall...
A key competitor with its Alzheimer's drug Leqembi; Lilly's improved safety profile intensifies competition but also validates and expands the overall market for anti-amyloid therapies.
Anavex Life Sciences Corp.
AVXL
Current price
$9.95
This clinical-stage company is developing treatments for Alzheimer's and benefits from increased investor interest and positive sentiment flowing into...
This clinical-stage company is developing treatments for Alzheimer's and benefits from increased investor interest and positive sentiment flowing into the entire neurodegenerative disease sector.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
The FDA's approval of a safer dosing protocol for Eli Lilly's Alzheimer's drug marks a pivotal moment for neurodegenerative treatments. This breakthrough not only improves a single therapy but signals a broader shift toward making powerful treatments more accessible, creating investment opportunities across the entire treatment ecosystem.
What You Need to Know
This group includes diverse companies from major pharmaceutical developers to innovative biotechs and specialized support firms. While some directly manufacture treatments, others provide essential services like brain imaging, diagnostics, and clinical trial management that enable the broader Alzheimer's treatment revolution.
Why These Stocks
These companies were handpicked by professional analysts to capture the full spectrum of the safer Alzheimer's treatment breakthrough. The selection includes established leaders with approved therapies, promising clinical-stage biotechs, and specialized firms whose technologies are critical to the successful deployment of these treatments.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+250.70%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 250.7% over the next year.
Stocks Rated Buy by Analysts
14 of 14 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Breakthrough Momentum
The FDA's approval of safer dosing for Alzheimer's drugs has created a domino effect of positive developments across the entire treatment landscape. This regulatory win signals major commercial potential for all companies in this space.
Massive Untapped Market
With over 6 million Americans living with Alzheimer's and safer treatments now emerging, these companies are targeting an enormous and largely underserved market. Safer treatments mean wider adoption and potentially billions in revenue.
The Full Innovation Chain
This group includes not just drug developers but also the diagnostic, imaging, and delivery technology companies that enable successful treatment. As the main therapies grow, so do the supporting technologies that make them possible.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.